Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Seagen Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1998-01-01

Employees: 3.2K

Market Cap: -

Website: http://www.seagen.com

Clinical Trials

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

First Posted Date: 2018-02-07

Last Posted Date: 2020-02-25

Lead Sponsor: Seagen Inc.

Registration Number: NCT03424473

A Safety Study of SGN-CD48A in Patients With Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: SGN-CD48A

First Posted Date: 2017-12-20

Last Posted Date: 2019-09-18

Lead Sponsor: Seagen Inc.

Target Recruit Count: 14

Registration Number: NCT03379584

Locations: 🇺🇸
University of California at San Francisco, San Francisco, California, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

and more 3 locations

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Phase 1

Completed

Conditions: Triple Negative Breast Neoplasms

Interventions: Drug: ladiratuzumab vedotin
Drug: Pembrolizumab

First Posted Date: 2017-10-16

Last Posted Date: 2024-12-20

Lead Sponsor: Seagen Inc.

Target Recruit Count: 186

Registration Number: NCT03310957

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸
Chao Family Comprehensive Cancer Center University of California Irvine, Orange, California, United States

and more 47 locations

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Phase 2

Completed

Conditions: Endometrium Cancer
Esophagus Cancer
Lung Cancer, Nonsmall Cell
Squamous Cell Carcinoma of the Head and Neck
Ovary Cancer
Cervix Cancer
Prostate Cancer
Bladder Cancer

Interventions: Drug: Tisotumab Vedotin

First Posted Date: 2017-08-10

Last Posted Date: 2021-11-04

Lead Sponsor: Seagen Inc.

Target Recruit Count: 5

Registration Number: NCT03245736

Locations: 🇺🇸
Brian Slomovitz, Miami, Florida, United States
🇬🇧
Johann de Bono, Chelsea, United Kingdom
🇬🇧
Beatson Cancer Centre, Glasgow, United Kingdom

and more 1 locations

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Adenocarcinoma

Interventions: Drug: Trastuzumab
Drug: Tucatinib

First Posted Date: 2017-02-06

Last Posted Date: 2024-11-26

Lead Sponsor: Seagen Inc.

Target Recruit Count: 117

Registration Number: NCT03043313

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States

and more 53 locations

A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: SGN-CD352A

First Posted Date: 2016-11-03

Last Posted Date: 2019-08-12

Lead Sponsor: Seagen Inc.

Target Recruit Count: 27

Registration Number: NCT02954796

Locations: 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States

and more 8 locations

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung
Carcinoma, Renal Cell
Breast Neoplasms
Urinary Bladder Neoplasm
Carcinoma, Squamous Cell of Head and Neck
Colorectal Neoplasms
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma

Interventions: Drug: SGN-2FF
Drug: pembrolizumab

First Posted Date: 2016-11-02

Last Posted Date: 2019-07-19

Lead Sponsor: Seagen Inc.

Target Recruit Count: 47

Registration Number: NCT02952989

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
University of Colorado Hospital / University of Colorado, Aurora, Colorado, United States

and more 8 locations

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Phase 2

Terminated

Conditions: Transformed Lymphoma / DLBCL
Diffuse, Large B-Cell, Lymphoma
Follicular Lymphoma, Grade 3b

Interventions: Drug: denintuzumab mafodotin
Drug: rituximab
Drug: cyclophosphamide
Drug: doxorubicin
Drug: vincristine
Drug: prednisone

First Posted Date: 2016-08-04

Last Posted Date: 2019-03-11

Lead Sponsor: Seagen Inc.

Target Recruit Count: 24

Registration Number: NCT02855359

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Saint Bernards Cancer Center, Jonesboro, Arkansas, United States
🇺🇸
City of Hope, Duarte, California, United States

and more 32 locations

A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: SGN-CD123A

First Posted Date: 2016-07-28

Last Posted Date: 2018-05-14

Lead Sponsor: Seagen Inc.

Target Recruit Count: 17

Registration Number: NCT02848248

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
University of Colorado Hospital / University of Colorado, Aurora, Colorado, United States

and more 4 locations

Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: 33A
Drug: placebo
Drug: azacitidine
Drug: decitabine

First Posted Date: 2016-05-30

Last Posted Date: 2018-12-12

Lead Sponsor: Seagen Inc.

Target Recruit Count: 240

Registration Number: NCT02785900

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Pacific Hematology Oncology Associates, San Francisco, California, United States

and more 125 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy